Strensiq FDA Approval History
FDA Approved: Yes (First approved October 23, 2015)
Brand name: Strensiq
Generic name: asfotase alfa
Dosage form: Injection
Company: Alexion Pharmaceuticals, Inc.
Treatment for: Hypophosphatasia
Strensiq (asfotase alfa) is a tissue nonspecific alkaline phosphatase enzyme replacement therapy indicated for the treatment of patients with perinatal, infantile and juvenile-onset hypophosphatasia (HPP).
Development Timeline for Strensiq
|Oct 23, 2015||ApprovalFDA Approves Strensiq (asfotase alfa) for Perinatal, Infantile and Juvenile-Onset Hypophosphatasia|
|Dec 30, 2014||Alexion Completes Rolling BLA Submission to FDA for Asfotase Alfa for Hypophosphatasia|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.